Identification of an HLA-A*0201-restricted cytotoxic T lymphocyte epitope from the lung carcinoma antigen, Lengsin

International Journal of Oncology

Volumn 39, Issue 4, 2011, Pages 1041-1049

  Nakatsugawa, Munehide ^a   Horie, Kazutaka ^a   Yoshikawa, Toshiaki ^a   Shimomura, Manami ^a   Kikuchi, Yamato ^a   Sakemura, Noriko ^a   Suzuki, Shiro ^a   Nobuoka, Daisuke ^a   Hirohashi, Yoshihiko ^b   Torigoe, Toshihiko ^b   Harada, Kenji ^c   Takasu, Hideo ^c   Sato, Noriyuki ^b   Nakatsura, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Cytotoxic T lymphocyte epitope; HLA A*0201 restricted; Lengsin; Lung carcinoma antigen

Indexed keywords

EPITOPE; GLUTAMATE AMMONIA LIGASE; HLA A ANTIGEN; LENGSIN; LENS PROTEIN; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HLA A*02:01 ANTIGEN; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; LGSN PROTEIN, HUMAN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN DETECTION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PROCESSING; ADENOCARCINOMA; ALGORITHM; ANIMAL; CELL STRAIN COS1; CERCOPITHECUS; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; METHODOLOGY; MOUSE MUTANT; PROTEIN BINDING; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADENOCARCINOMA; ALGORITHMS; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; EPITOPES, T-LYMPHOCYTE; GLUTAMATE-AMMONIA LIGASE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79960887776     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1089     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Morgan RA, Dudley ME, Wunderlich JR, et al: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314: 126-129, 2006. (Pubitemid 44547756)
3. Johnson LA, Morgan RA, Dudley ME, et al: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546, 2009.
4. Robbins PF, Morgan RA, Feldman SA, et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917-924, 2011.
5. Browning M and Krausa P: Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol Today 17: 165-170, 1996. (Pubitemid 26113084)
6. Viatte S, Alves PM and Romero P: Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. Immunol Cell Biol 84: 318-330, 2006.
7. van der Bruggen P, Bastin J, Gajewski T, et al: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24: 3038-3043, 1994.
8. Celis E, Tsai V, Crimi C, et al: Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91: 2105-2109, 1994. (Pubitemid 24092051)
9. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA and Perarnau B: HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185: 2043-2051, 1997. (Pubitemid 27265987)
10. Firat H, Garcia-Pons F, Tourdot S, et al: H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinicalevaluation of antitumor immunotherapeutic strategies. Eur J Immunol 29: 3112-3121, 1999. (Pubitemid 29484201)
11. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P and Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97: 4796-4801, 2000. (Pubitemid 30238637)
12. Komori H, Nakatsura T, Senju S, et al: Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 12: 2689-2697, 2006.
13. Passoni L, Scardino A, Bertazzoli C, et al: ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 99: 2100-2106, 2002. (Pubitemid 34525494)
14. Hassainya Y, Garcia-Pons F, Kratzer R, et al: Identification of naturally processed HLA-A2 - restricted proinsulin epitopes by reverse immunology. Diabetes 54: 2053-2059, 2005. (Pubitemid 40911268)
15. Alves PM, Faure O, Graff-Dubois S, et al: EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res 63: 8476-8480, 2003. (Pubitemid 37553156)
16. Nakatsugawa M, Hirohashi Y, Torigoe T, et al: Novel spliced form of a lens protein as a novel lung cancer antigen, Lengsin splicing variant 4. Cancer Sci 100: 1485-1493, 2009.
17. Lang RA: Apoptosis in mammalian eye development: lens morphogenesis, vascular regression and immune privilege. Cell Death Differ 4: 12-20, 1997.
18. Martin WD, Egan RM, Stevens JL and Woodward JG: Lens-specific expression of a major histocompatibility complex class I molecule disrupts normal lens development and induces cataracts in transgenic mice. Invest Ophthalmol Vis Sci 36: 1144-1154, 1995.
19. Akatsuka Y, Goldberg TA, Kondo E, et al: Efficient cloning and expression of HLA class I cDNA in human B-lymphoblastoid cell lines. Tissue Antigens 59: 502-511, 2002. (Pubitemid 35034470)
20. Hirohashi Y, Torigoe T, Maeda A, et al: An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8: 1731-1739, 2002. (Pubitemid 34633728)
21. Tsukahara T, Kawaguchi S, Torigoe T, et al: HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papilloma-virus binding factor. J Transl Med 7: 44, 2009.
22. Wang XM, Terasaki PI, Rankin GW Jr, Chia D, Zhong HP and Hardy S: A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol 37: 264-270, 1993. (Pubitemid 23343716)
23. Kondo M, Sakuta K, Noguchi A, et al: Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 10: 842-856, 2008.
24. Tanzarella S, Fleischhauer K, van Endert P, Bordignon C and Traversari C: Characterization of antigenic peptide epitopes by reverse immunology: induction of cytotoxic T lymphocytes specific for exogenous peptide only. Int J Cancer 72: 912-915, 1997. (Pubitemid 27431539)
25. Noppen C, Levy F, Burri L, et al: Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer 87: 241-246, 2000. (Pubitemid 30434353)
26. So T, Hanagiri T, Chapiro J, et al: Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules. Cancer Immunol Immunother 56: 259-269, 2007. (Pubitemid 44833099)
27. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA and Kawakami Y: Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58: 4895-4901, 1998. (Pubitemid 28503687)
28. Yee C, Savage PA, Lee PP, Davis MM and Greenberg PD: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162: 2227-2234, 1999. (Pubitemid 29288845)
29. + T-cell clones in patients after NY-ESO-1 peptide vaccination. Int J Cancer 121: 2042-2048, 2007.
30. Wilde S, Sommermeyer D, Frankenberger B, et al: Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 114: 2131-2139, 2009.
31. Alexander-Miller MA, Leggatt GR and Berzofsky JA: Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 93: 4102-4107, 1996. (Pubitemid 26144250)
32. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA and Yang JC: High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162: 989-994, 1999. (Pubitemid 29035425)
33. Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT and Schlom J: Multiple costimulatory modalities enhance CTL avidity. J Immunol 174: 5994-6004, 2005. (Pubitemid 40663786)
34. + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J Immunol 171: 2251-2261, 2003.
35. Oh S, Perera LP, Burke DS, Waldmann TA and Berzofsky JA: IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci USA 101: 15154-15159, 2004. (Pubitemid 39391734)
36. Sadovnikova E, Jopling LA, Soo KS and Stauss HJ: Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 28: 193-200, 1998. (Pubitemid 28048290)
37. Savage P, Gao L, Vento K, et al: Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103: 4613-4615, 2004. (Pubitemid 38745991)
38. Kronig H, Hofer K, Conrad H, et al: Allorestricted T lymphocyteswith a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int J Cancer 125: 649-655, 2009.
39. Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF and Rosenberg SA: Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10: 4688-4698, 2004. (Pubitemid 38955519)
40. Vonderheide RH, Hahn WC, Schultze JL and Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679, 1999. (Pubitemid 29302920)
41. Ayyoub M, Migliaccio M, Guillaume P, et al: Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 31: 2642-2651, 2001. (Pubitemid 32898731)
42. Purbhoo MA, Li Y, Sutton DH, et al: The HLA-A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol Cancer Ther 6: 2081-2091, 2007. (Pubitemid 47052499)
43. Chen DY, Vance BA, Thompson LB, Domchek SM and Vonderheide RH: Differential lysis of tumors by polyclonal T cell lines and T cell clones specific for hTERT. Cancer Biol Ther 6: 1991-1996, 2007. (Pubitemid 351590414)
44. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M and Lee PP: Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9: 1377-1382, 2003. (Pubitemid 37466186)
45. Yoshikawa T, Nakatsugawa M and Suzuki S: HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells. Cancer Sci 102: 918-925, 2011.
46. Rock KL and Goldberg AL: Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 17: 739-779, 1999. (Pubitemid 29241139)
47. Wherry EJ, Golovina TN, Morrison SE, Sinnathamby G, McElhaugh MJ, Shockey DC and Eisenlohr LC: Re-evaluating the generation of a 'proteasome-independent' MHC class I-restricted CD8 T cell epitope. J Immunol 176: 2249-2261, 2006. (Pubitemid 43201672)
48. Valmori D, Gileadi U, Servis C, et al: Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med 189: 895-906, 1999.
49. Luckey CJ, King GM, Marto JA, et al: Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomalepitope generation in the cytosol. J Immunol 161: 112-121, 1998. (Pubitemid 28285513)
50. Cox AL, Skipper J, Chen Y, et al: Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719, 1994. (Pubitemid 24185883)
51. Schirle M, Keilholz W, Weber B, et al: Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30: 2216-2225, 2000. (Pubitemid 30655761)
52. + T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood 108: 2662-2668, 2006.